Share, email, print, bookmark SOURCE reports.

In full transparency, the following press release was submitted to SOURCE media through its business wire service.


[broadstreet zone=”53820″]

FRAMINGHAM – Olaris, Inc, a precision medicine company leveraging metabolomics and machine learning for the discovery and development of Biomarkers of Response (BoRs) to optimize treatments and patient outcomes, announced the company’s presentation on the identification of metabolic reprograming associated with CDK4/6 sensitivity and resistance has been selected for a poster presentation at the upcoming 2022 American Association for Cancer Research (AACR) annual meeting, to be held April 8-13.

The presentation, led by Olaris Metabolite Scientist Dr. Chandrashekhar Honrao, will describe the recent results of a collaboration between Olaris and the Dana Farber Cancer Institute.

[broadstreet zone=”59948″]

Using a human breast cancer cell line model and isotope tracers, researchers determined that glucose metabolism was altered following treatment with two CDK4/6 inhibitors, palbociclib and abemaciclib. They also found that cells resistant to the drugs had alterations in different metabolic pathways, representing the first-ever evidence of metabolite signatures specific to two different CDK4/6 inhibitors.

CDK4/6 inhibitors are often used in combination with hormone therapy to treat patients with hormone receptor-positive, HER2-negative metastatic breast cancer, yet almost 20% of patients never respond to treatment and all patients eventually develop acquired treatment resistance. Understanding the metabolic pathways involved in response and resistance to CDK4/6 inhibitor treatment has the potential to allow patients and their clinicians to determine whether a particular drug regimen will be impactful to their care.

[broadstreet zone=”53130″]

“We are enthusiastic to see the results of these novel in vitro studies. We have begun analyses to examine whether these findings translate to clinical samples, potentially leading to clinical biomarkers of response for each specific CDK4/6 inhibitor,” said Dr. Elizabeth O’Day, CEO and Founder of Olaris. “We are also exploring whether targeting the pathways associated with resistance can restore CDK4/6i sensitivity. This could lead to novel therapeutic targets or treatment regimens to improve patient outcomes.”

The AACR annual meeting is the focal point of the cancer research community, bringing together scientists, clinicians, patients and those in the patient advocacy communities. The meeting highlights cutting-edge research in all fields surrounding cancer prevention, diagnosis, and treatment. The conference takes place in Boston and virtually online from April 8-13.

Olaris is working to fundamentally change how diseases are treated by leveraging our proprietary metabolomics and machine learning platform to identify Biomarker of Response (BoR) signatures. Olaris develops BoR in vitro diagnostics (IVDs) to empower patients, providers, and biopharma to pursue the most effective treatment. The company is headquartered in Framingham.

By editor

Susan Petroni is the former editor for SOURCE. She is the founder of the former news site, which as of May 1, 2023, is now a self-publishing community bulletin board. The website no longer has a journalist but a webmaster.